Biocytogen Pharmaceuticals, a biotechnology company focused on the generation and validation of novel antibody-based therapeutics and specialized animal models for partners worldwide, opened a new 37,000 sq.-ft. facility in Waltham, MA for its US-based subsidiary, Biocytogen Boston Corp. The facility will triple Biocytogen Boston’s workspace, and includes a climate-controlled 4,000 cage vivarium, cell culture and procedure suites, and an open design concept to facilitate collaboration among employees and visiting clients.

The new location will focus on preclinical contract research services and the distribution of specialized animal model products (“BioMice”) to support the increasing demand for projects from clients in North America and Europe. As a provider of humanized animal models worldwide, Biocytogen offers more than 500 strains of these specialized mice for generating and testing novel antibody and cell-based therapeutics in vivo.

Furthermore, Biocytogen’s flagship RenMab model and its second-generation RenMice-based platforms are powerful tools used to discover new fully human antibodies that can be developed into multiple therapeutic modalities, including naked antibodies, bi/trispecific antibodies, bispecific ADC, CAR-T, and CAR-NK. In addition to the research and technology teams, the company’s new location will support Biocytogen’s expanding business development initiatives, including establishing new client partnerships and out-licensing new products.

Qingcong Lin, senior vice president of Biocytogen and CEO of Biocytogen Boston, said, “This move signifies an exciting new chapter for Biocytogen. Our team’s dedication to providing high-quality preclinical models and services has led to the exponential growth of our business over the past 5 years, across both North America and Europe. We’re extremely excited for the opportunity to continue our commitment to experimental excellence our clients depend on and come to expect, but on a larger scale. We look forward to welcoming current and prospective clients/partners to this state-of-the-art facility to accelerate further collaboration.”